Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group

Neuro-Oncology

Volumn 15, Issue 10, 2013, Pages 1438-1444

  Macdonald, Tobey J ^a   Vezina, Gilbert ^b   Stewart, Clinton F ^c   Turner, David ^c   Pierson, Christopher R ^d   Chen, Lu ^e   Pollack, Ian F ^f   Gajjar, Amar ^c   Kieran, Mark W ^g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^g BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

childhood; cilengitide; high grade glioma

Indexed keywords

CILENGITIDE; LOMUSTINE; TEMOZOLOMIDE;

ADOLESCENT; ADULT; APNEA; AREA UNDER THE CURVE; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CATHETER INFECTION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COGNITIVE DEFECT; CONSCIOUSNESS LEVEL; CONSTIPATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDUCED HEADACHE; DRUG TOXICITY; DYSPNEA; EXON; FACIAL NERVE DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENETIC VARIABILITY; GLIOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HUMAN; HUMAN TISSUE; HYDROCEPHALUS; HYPOPHOSPHATEMIA; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MULTIMODALITY CANCER THERAPY; MUSCLE WEAKNESS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PAIN; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; RECURRENT CANCER; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SKIN DISEASE; TANDEM MASS SPECTROMETRY; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BLEEDING; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; VOMITING;

CHILDHOOD; CILENGITIDE; HIGH-GRADE GLIOMA;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; INFANT; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SALVAGE THERAPY; SNAKE VENOMS; SURVIVAL RATE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84884998198     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not058     Document Type: Article

References (25)

1. Pollack IF, Hamilton RL, Sobol RW, et al. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol. 2006;24:3431-3437. (Pubitemid 46638900)
2. CohenKJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of highgrade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011;13:317-323.
3. Reardon DA, Perry JR, Brandes AA, Jalali R, WickW. Advances in malignant glioma drug discovery. Expert Opin Drug Discov. 2011;6:739-753.
4. MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neuro Oncol. 2011;13:1049-1058.
5. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17:1359-1370.
6. Tabatabai G, Tonn JC, Stupp R,Weller M. The role of integrins in glioma biology and anti-glioma therapies. Curr Pharm Des. 2011;17: 2402-2410.
7. Tabatabai G, Weller M, Nabors B, et al. Targeting integrins in malignant glioma. Target Oncol. 2010;5:175-181.
8. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrintargeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008;17:1225-1235.
9. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 2001;48:151-157. (Pubitemid 32039837)
10. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery. 2006;59:1304-1312. (Pubitemid 44949775)
11. Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer. 2011;2:1159-1165.
12. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012;106: 147-153.
13. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610-5617.
14. Nabors LB, Mikkelsen T, Rosenfeld SS, et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007;25:1651-1657. (Pubitemid 46797943)
15. MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol. 2008;26:919-924. (Pubitemid 351398085)
16. Eskens FA, Dumez H, Hoekstra R, et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer. 2003;39:917-926. (Pubitemid 36428623)
17. D'argenio DZ, Schumitzky A, Wang X. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource, Los Angeles, 2009.
18. Stupp R, HegiME,Neyns B, et al. Phase I/IIa study of cilengitide andtemozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712-2718.
19. Alghisi GC, Ponsonnet L, Rü egg C. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One. 2009;4:e4449.
20. Maurer GD, Tritschler I, Adams B, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol. 2009;11:747-756.
21. Mikkelsen T, Brodie C, Finniss S, et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer. 2009;124:2719-2727.
22. Lomonaco SL, Finniss S, Xiang C, et al. Cilengitide induces autophagymediated cell death in glioma cells. Neuro Oncol. 2011;13:857-865.
23. Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012;118:5601-5607.
24. Nisato RE, Tille JC, Jonczyk A, et al. Alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis. 2003;6:105-119. (Pubitemid 38173862)
25. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol. 2011;6:2.